Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
Related Questions
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose-fractionation for locally advance NSCLC now getting RT alone?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
